Headlands Technologies LLC Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Headlands Technologies LLC bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 8,142 shares of the company’s stock, valued at approximately $224,000.

Other hedge funds also recently modified their holdings of the company. American Century Companies Inc. boosted its stake in Intellia Therapeutics by 5.9% during the 3rd quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock worth $8,449,000 after acquiring an additional 14,863 shares during the last quarter. Wellington Management Group LLP boosted its stake in Intellia Therapeutics by 1.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after acquiring an additional 36,630 shares during the last quarter. Cyndeo Wealth Partners LLC boosted its stake in Intellia Therapeutics by 13.8% during the 4th quarter. Cyndeo Wealth Partners LLC now owns 8,236 shares of the company’s stock worth $251,000 after acquiring an additional 1,000 shares during the last quarter. Raymond James & Associates boosted its stake in Intellia Therapeutics by 28.7% during the 4th quarter. Raymond James & Associates now owns 134,371 shares of the company’s stock worth $4,097,000 after acquiring an additional 29,997 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Intellia Therapeutics by 13.3% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock worth $1,104,000 after acquiring an additional 4,255 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $73.00 price target on shares of Intellia Therapeutics in a research note on Thursday, June 27th. Citigroup cut their price target on shares of Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. BMO Capital Markets lifted their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Intellia Therapeutics Trading Up 4.9 %

Shares of NASDAQ:NTLA traded up $1.27 on Tuesday, hitting $27.28. The company had a trading volume of 1,418,039 shares, compared to its average volume of 1,573,584. Intellia Therapeutics, Inc. has a 1-year low of $19.37 and a 1-year high of $46.00. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of -5.02 and a beta of 1.82. The stock has a 50 day moving average price of $24.04 and a 200 day moving average price of $25.72.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.29. The company had revenue of $28.94 million during the quarter, compared to analyst estimates of $15.60 million. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -4.98 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.